Decreased DAB2IP gene expression, which could be induced by fractionated irradiation, is associated with resistance to γ-rays and α-particles in prostate cancer cells

Chen Yang, Hui He, Tingting Zhang, Ying Chen, Zhaolu KongMolecular 2016 · DOI

Abstract

External beam radiation therapy is a standard treatment for prostate cancer (PCa), but acquired radioresistance often limits its efficacy. This study investigates the role of the tumor suppressor gene DAB2IP in this process. Preliminary results indicated that loss of DAB2IP expression leads to resistance to γ-rays. By fractionally irradiating PCa cells, researchers observed a continuous reduction in DAB2IP mRNA levels alongside increased ATM expression. While α-particles were generally more effective than γ-rays, DAB2IP-deficient cells remained resistant to high-LET radiation. These findings suggest that radiotherapy-induced DAB2IP downregulation contributes to acquired radioresistance in PCa patients.

Introduction

Radiotherapy is a cornerstone of prostate cancer management, yet many patients develop resistance over time. A key player in aggressive PCa is DAB2IP (Disabled homolog 2 interactive protein), a tumor suppressor often absent in aggressive, metastatic cases. This study addresses whether standard clinical practice—fractionated radiation—actually causes the loss of DAB2IP and if such loss can be overcome by high-Linear Energy Transfer (LET) radiation, specifically α-particles.

Methods

The researchers utilized the PC3 human prostate cancer cell line, creating a DAB2IP-deficient model (shDAB2IP) via shRNA-lentiviral knockdown. A fractionated irradiation protocol was designed to mimic clinical schedules, involving 12 daily doses of 2 Gy γ-rays over a 19-day period.

Experimental timeline and molecular response to fractionated irradiation.

Key experimental techniques included comparing low-LET γ-rays ($^{137}$Cs) with high-LET α-particles ($^{241}$Am). Molecular changes were tracked using RT-qPCR and Western blotting, focusing on DAB2IP and DNA Damage Response (DDR) markers like ATM, ATR, and DNA-PKcs. Radiosensitivity was assessed through colony formation assays (CFA).

Results and Discussion

Treatment-Induced Gene Suppression

A critical finding was that fractionated radiation progressively reduces DAB2IP expression. As shown in Figure 3B, mRNA levels dropped continuously through the 12-fraction cycle, reaching their lowest point at the end of the treatment period. This suggests that the treatment itself may drive the development of a more resistant cellular phenotype by selecting for or inducing DAB2IP loss.

Divergent Resistance Mechanisms

The loss of DAB2IP re-wires the cellular response to DNA damage differently depending on the radiation type:

  • Against γ-rays: Resistance is primarily mediated by the ATM pathway. Irradiation induced a significant increase in ATM mRNA in DAB2IP-deficient cells (Figure 3C).
  • Against α-particles: Resistance appears driven by the ATR pathway. While α-particles were significantly more effective than γ-rays overall (Relative Biological Effectiveness of ~9-11), shDAB2IP cells still exhibited significantly higher survival rates than controls when hit with high-LET radiation.

Therapeutic Implications

Inhibiting ATM with the specific inhibitor KU55933 successfully sensitized cells to γ-rays but failed to improve the response to α-particles in DAB2IP-deficient cells. This shift to ATR-dependency for high-LET radiation suggests that combining α-particle therapy with ATR inhibitors might be a more potent strategy to overcome acquired radioresistance.

Conclusion

This study demonstrates that radiotherapy can induce the downregulation of the tumor suppressor DAB2IP, leading to acquired radioresistance in prostate cancer. While α-particles offer a powerful alternative, DAB2IP deficiency provides a survival advantage even against high-LET radiation. Future clinical strategies may need to incorporate ATR inhibitors alongside advanced radiation therapies to effectively target these resistant cell populations.

Summary updated

Abstract

External beam radiation therapy, alone or combined with androgen deprivation, is a well‑established treatment for prostate cancer (PCa). However, not all patients benefit from radiotherapy due to congenital or acquired radioresistance. The preliminary results of the present study indicated that the loss of disabled homolog 2 interactive protein (DAB2IP) expression in PCa and normal prostate epithelia results in the resistance to γ‑rays. To further explore the association between DAB2IP and ionizing radiation (IR), PCa cells were fractionally irradiated 12 times with 2 Gy of γ‑rays and the change in DAB2IP mRNA expression was monitored. Notably, along with a continuous reduction of DAB2IP expression levels, increased expression levels of ataxia‑telangiectasia mutated (ATM) was observed in IR‑treated cells. In order to improve the sensitivity of DAB2IP‑deficient cells to IR, α‑particles, a type of high linear energy transfer radiation and KU55933, an ATM inhibitor, were used in the current study. It was determined that α‑particle irradiations were more effective than γ‑rays on cells expressing expected and decreased levels of DAB2IP. However, cells with a dysfunctional DAB2IP gene were resistant to α‑particle irradiation. Treatment with KU55933 did not enhance cell sensitivity to α‑irradiation. Therefore, this suggested that DAB2IP downregulation induced by radiotherapy may be associated with acquired radioresistance in patients with PCa.
BibTeX
@inproceedings{yang2016decreased,
  author = {Chen Yang and Hui He and Tingting Zhang and Ying Chen and Zhaolu Kong},
  title = {{Decreased DAB2IP gene expression, which could be induced by fractionated irradiation, is associated with resistance to γ-rays and α-particles in prostate cancer cells}},
  booktitle = {Molecular},
  year = {2016},
  doi = {10.3892/mmr.2016.5281},
}
Figure